Receptor Binding and Tyrosine Kinase Activation by Insulin Analogues With Extreme Affinities Studied in Human Hepatoma HepG2 Cells

The insulin-receptor affinity of five human insulin analogues with one to four amino acid substitutions was measured with human hepatoma cells (HepG2). The binding affinities ranged from 0.05% for Asp B25 insulin, 18% for Asp B9 , Glu B27 insulin, 80% for Asp B28 insulin, and 327% for Asp B10 insulin to 687% for His A8 , His B4 , Glu B10 , His B27 insulin relative to human insulin. Binding constants obtained by competition experiments at steady state with [ 125 I]Tyr A14 -labeled insulin and unlabeled analogues and by kinetic studies with [ 125 I]Tyr A14 -labeled analogues and insulin gave essentially the same values. The kinetic studies showed that differences in affinity between analogues were due to differences in both dissociation and association rate constants. The affinity for insulinlike growth factor I receptor was low, ranging from B25 insulin to 0.6% for His A8 , His B4 , Glu B10 , His B27 insulin. The potencies of insulin analoguesin activation of the tyrosine kinase of solubilized and partially purified insulin receptors from HepG2 cells, measured with the exogenous substrate poly(Glu 80 -Tyr 20 ), ranked in the same order as the binding affinities, the actual values being somewhat elevated for the high-affinity analogues, however. We conclude that these human insulin analogues are active in insulin-receptor binding and tyrosine kinase stimulation but show wide variation in affinity.